Size | Price | Stock | Qty |
---|---|---|---|
500mg |
|
||
1g |
|
||
5g |
|
||
10g |
|
||
25g |
|
||
50g |
|
||
Other Sizes |
|
Purity: ≥98%
Quercetin (Sophoretin; NSC-9221; Kvercetin) is a natural flavonoid isolated from various vegetables, fruits and wine. Quercetin has been reported to possess a variety of biological activities including anti-inflammatory, anti-oxidant and pro-apoptotic functions in cancer cells. As a PI3K inhibitor with an IC50 range of 2.4–5.4 μMand as a stimulator of recombinant SIRT1, it inhibited tumor growth in various ways. Because it is advantageous for diabetics, quercetin is a component of many dietary supplements.
Targets |
PI3Kδ (IC50 = 2.4 μM); PI3Kγ (IC50 = 3 μM); PI3Kβ (IC50 = 5.4 μM); Autophagy; Mitophagy
|
---|---|
ln Vitro |
Quercetin, a flavonol and a plant-derived flavonoid, is a type of plant-based chemical, or phytochemical, that can be found in fruits, vegetables, leaves, and grains. Supplements, drinks, and foods may all contain it as an ingredient. It is being researched for a wide range of potential health benefits, including anti-inflammatory and antioxidant properties that have been suggested by several studies. With an IC50 range of 2.4 to 5.4 M, quercetin (Sophoretin) inhibits PI3K. It severely inhibited PI3K and Src kinases, only slightly affected Akt1/2, PKC, p38, and ERK1/2, and barely had any effect on PI3K and Src kinases.[1] Quercetin blocks TNF-induced LDH% release, EC-dependent neutrophil adhesion to bovine pulmonary artery endothelial cells (BPAEC), and BPAEC DNA synthesis and proliferation.[2]
|
ln Vivo |
Combination of Quercetin (75 mg/kg) and 2-Methoxyestradiol enhances inhibition of human prostate cancer LNCaP and PC-3 cells xenograft tumor growth.[3]
|
Enzyme Assay |
Quercetin is a type of plant-based chemical, or phytochemical, known as a flavonol and a plant-derived flavonoid found in fruits, vegetables, leaves and grains. It also may be used as an ingredient in supplements, beverages or foods. In several studies, it may have anti-inflammatory and antioxidant properties, and it is being investigated for a wide range of potential health benefits. Quercetin (Sophoretin) is a PI3K inhibitor with IC50 of 2.4 – 5.4 μM. It strongly abrogated PI3K and Src kinases, mildly inhibited Akt1/2, and slightly affected PKC, p38 and ERK1/2. Quercetin inhibits TNF-induced LDH% release, EC-dependent neutrophils adhesion to bovine pulmonary artery endothelial cells (BPAEC), and BPAEC DNA synthesis and proliferation.
|
Cell Assay |
Cells were treated with various concentrations of drug for 24 h.
|
Animal Protocol |
On the right back of mice, 2×108 LNCaP cells and 5 105 PC-3 cells suspended in 100 liters of matrigel and PBS are inoculated subcutaneously. Mice are randomly assigned to four groups (n=8 in each group) and treated intraperitoneally when xenograft tumors have grown to a volume of about 100 mm3.
|
References |
Molecular Formula |
C15H10O7
|
---|---|
Molecular Weight |
302.2357
|
Exact Mass |
302.0427
|
Elemental Analysis |
C, 59.61; H, 3.34; O, 37.05
|
CAS # |
117-39-5
|
Related CAS # |
Quercetin-d3;263711-79-1;Quercetin dihydrate;6151-25-3;Quercetin hydrate;849061-97-8;Quercetin;117-39-5;Quercetin-d5;263711-78-0;Quercetin-13C3
|
Appearance |
Solid powder
|
SMILES |
C1=CC(=C(C=C1C2=C(C(=O)C3=C(C=C(C=C3O2)O)O)O)O)O
|
InChi Key |
REFJWTPEDVJJIY-UHFFFAOYSA-N
|
InChi Code |
InChI=1S/C15H10O7/c16-7-4-10(19)12-11(5-7)22-15(14(21)13(12)20)6-1-2-8(17)9(18)3-6/h1-5,16-19,21H
|
Chemical Name |
2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxychromen-4-one
|
Synonyms |
NSC 9221; NCI-C60106; NSC 9219; Meletin; Quercetin; Kvercetin; Quercetine; Quercetol; Quertine; Sophoretin; Xanthaurine
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
DMSO: ~61 mg/mL (~201.8 mM)
Water: <1 mg/mL Ethanol: ~10 mg/mL (~33.1 mM) |
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (8.27 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (8.27 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: 2% DMSO+30% PEG 300+2% Tween 80+ddH2O: 6mg/mL Solubility in Formulation 4: 25 mg/mL (82.72 mM) in 0.5% CMC-Na/saline water (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 5: 10 mg/mL (33.09 mM) in 45% PEG300 5% Tween-80 50% Saline (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 6: 10 mg/mL (33.09 mM) in 50% PG 50% Saline (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 3.3086 mL | 16.5431 mL | 33.0863 mL | |
5 mM | 0.6617 mL | 3.3086 mL | 6.6173 mL | |
10 mM | 0.3309 mL | 1.6543 mL | 3.3086 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
NCT Number | Status | Interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
NCT01720147 | Active Recruiting |
Drug: Quercetin (dietary supplement) |
Fanconi Anemia | Children's Hospital Medical Center, Cincinnati |
July 2012 | Phase 1 |
NCT04907253 | Active Recruiting |
Drug: Quercetin Drug: Placebo |
Coronary Artery Disease | Montreal Heart Institute | June 4, 2021 | Phase 2 |
NCT04313634 | Active Recruiting |
Drug: Fisetin Drug: Quercetin |
Healthy | Sundeep Khosla, M.D. | June 9, 2020 | Phase 2 |
NCT02226484 | Completed | Drug: Quercetin | GERD Reflux |
University of North Carolina, Chapel Hill |
August 2014 | Phase 1 |
NCT03476330 | Recruiting | Drug: Quercetin (dietary supplement) |
Fanconi Anemia Squamous Cell Carcinoma |
Children's Hospital Medical Center, Cincinnati |
May 8, 2018 | Phase 2 |
Quercetin combined with 2-ME enhanced inhibition of PC-3 xenograft tumor growth. Yang F, et al. PLoS One. 2015, 10(5), e0128277. td> |
Quercetin combined with 2-ME decreased pAKT protein expression in PC-3 and LNCaP xenograft tumor tissues. |
Quercetin combined with 2-ME decreased VEGF protein and mRNA in PC-3 and LNCaP xenograft tumor tissues. td> |